OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Northern Trust Corp

Northern Trust Corp raised its position in OPKO Health, Inc. (NASDAQ:OPK) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,697,774 shares of the biotechnology company’s stock after acquiring an additional 164,847 shares during the quarter. Northern Trust Corp owned approximately 0.54% of OPKO Health worth $5,436,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Cibc World Markets Corp purchased a new stake in OPKO Health in the fourth quarter valued at approximately $45,000. Zacks Investment Management acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $49,000. Ieq Capital LLC acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $52,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $91,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $102,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OPK has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating for the company. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. Finally, StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $2.75.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $1.74 per share, with a total value of $348,000.00. Following the transaction, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired 767,434 shares of company stock worth $1,238,312 in the last 90 days. 49.69% of the stock is owned by company insiders.

OPKO Health Stock Performance

OPKO Health stock opened at $1.33 on Wednesday. The stock has a market cap of $1.05 billion, a PE ratio of -7.00 and a beta of 1.42. The stock has a 50-day moving average price of $1.49 and a 200 day moving average price of $1.55. OPKO Health, Inc. has a 52 week low of $1.19 and a 52 week high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company’s revenue for the quarter was down 13.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) EPS. Equities research analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.